A candidate vaccine spurs both younger and older people to make antibodies against the coronavirus SARS-CoV-2, according to early trial results. The vaccine, which is under development by Johnson & Johnson, headquartered in New Brunswick, New Jersey, uses a harmless virus to inject cells with the instructions for making the SARS-CoV-2 spike protein.
Almost 100% of study participants aged 18–55 years had developed potent antibodies against the virus 57 days after receiving a single low dose of the jab. In a separate arm of the trial, the same regimen triggered the development of antibodies in 96% of participants aged 65 years and older 29 days after vaccination. Side effects were largely mild or moderate, and antibodies persisted until at least 71 days after inoculation.
The results of larger efficacy trials of the vaccine are pending.
https://www.nature.com/articles/d41586-020-00502-w
Article Sadoff et al New Engl J Med 2021
Coronavirus Cases:
93.616 million
Deaths:
2.004 million
Recovered:
66.921 million
Please see the link below.
https://www.nejm.org/doi/full/10.1056/NEJMoa2034201
Please see the link below.
https://www.nejm.org/doi/full/10.1056/NEJMoa2034201
Dear Ijaz Durrani, the following link might be useful, please have a look:
Preprint Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccin...
Dear All --please take a look at the following useful link:
Preprint Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccin...
&
https://www.isrctn.com/ISRCTN14722499
To date the m-RNA based vaccines have shown better results of >90% efficacy (Pfizer, Moderna, Astra-Zenica) compared with the inactive virus based vaccines with an efficacy of about 50% ( CoronaVac China).
https://www.nature.com/articles/d41586-021-00094-z
- Badges
- Science topic
- Similar topics
- Biological Science
- Microbiology
- Virology
- Virus